Medication: Difference between revisions

Line 473:

[[World Trade Organization|World Trade Organization]] negotiations in the 1990s, including the [[TRIPS Agreement|TRIPS Agreement]] and the [[Doha Declaration|Doha Declaration]], have centered on issues at the intersection of international trade in pharmaceuticals and [[intellectual property rights|intellectual property rights]], with developed world nations seeking strong intellectual property rights to protect investments made to develop new drugs, and developing world nations seeking to promote their generic pharmaceuticals industries and their ability to make medicine available to their people via [[compulsory licenses|compulsory licenses]].

[[:en:World Trade Organization|World Trade Organization]] negotiations in the 1990s, including the [[:en:TRIPS Agreement|TRIPS Agreement]] and the [[:en:Doha Declaration|Doha Declaration]], have centered on issues at the intersection of international trade in pharmaceuticals and [[:en:intellectual property rights|intellectual property rights]], with developed world nations seeking strong intellectual property rights to protect investments made to develop new drugs, and developing world nations seeking to promote their generic pharmaceuticals industries and their ability to make medicine available to their people via [[:en:compulsory licenses|compulsory licenses]].

Line 479:

[[Novartis|Novartis]] fought a protracted battle with the government of India over the patenting of its drug, [[Gleevec|Gleevec]], in India, which ended up in a Supreme Court in a case known as [[Novartis v. Union of India & Others|Novartis v. Union of India & Others]]. The Supreme Court ruled narrowly against Novartis, but opponents of patenting drugs claimed it as a major victory.

[[Novartis|Novartis]] fought a protracted battle with the government of India over the patenting of its drug, [[Gleevec|Gleevec]], in India, which ended up in a Supreme Court in a case known as [[:en:Novartis v. Union of India & Others|Novartis v. Union of India & Others]]. The Supreme Court ruled narrowly against Novartis, but opponents of patenting drugs claimed it as a major victory.

===Environmental issues===

@@ Line 473: / Line 473: @@
 <!--T:149-->
-[[World Trade Organization|World Trade Organization]] negotiations in the 1990s, including the [[TRIPS Agreement|TRIPS Agreement]] and the [[Doha Declaration|Doha Declaration]], have centered on issues at the intersection of international trade in pharmaceuticals and [[intellectual property rights|intellectual property rights]], with developed world nations seeking strong intellectual property rights to protect investments made to develop new drugs, and developing world nations seeking to promote their generic pharmaceuticals industries and their ability to make medicine available to their people via [[compulsory licenses|compulsory licenses]].
+[[:en:World Trade Organization|World Trade Organization]] negotiations in the 1990s, including the [[:en:TRIPS Agreement|TRIPS Agreement]] and the [[:en:Doha Declaration|Doha Declaration]], have centered on issues at the intersection of international trade in pharmaceuticals and [[:en:intellectual property rights|intellectual property rights]], with developed world nations seeking strong intellectual property rights to protect investments made to develop new drugs, and developing world nations seeking to promote their generic pharmaceuticals industries and their ability to make medicine available to their people via [[:en:compulsory licenses|compulsory licenses]].
 <!--T:150-->
@@ Line 479: / Line 479: @@
 <!--T:151-->
-[[Novartis|Novartis]] fought a protracted battle with the government of India over the patenting of its drug, [[Gleevec|Gleevec]], in India, which ended up in a Supreme Court in a case known as [[Novartis v. Union of India & Others|Novartis v. Union of India & Others]].  The Supreme Court ruled narrowly against Novartis, but opponents of patenting drugs claimed it as a major victory.
+[[Novartis|Novartis]] fought a protracted battle with the government of India over the patenting of its drug, [[Gleevec|Gleevec]], in India, which ended up in a Supreme Court in a case known as [[:en:Novartis v. Union of India & Others|Novartis v. Union of India & Others]].  The Supreme Court ruled narrowly against Novartis, but opponents of patenting drugs claimed it as a major victory.
 ===Environmental issues=== <!--T:152-->